Teacher Retirement System of Texas Buys 45,431 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Teacher Retirement System of Texas raised its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 73.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,644 shares of the company's stock after buying an additional 45,431 shares during the period. Teacher Retirement System of Texas owned about 0.07% of Option Care Health worth $3,762,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Murphy & Mullick Capital Management Corp bought a new position in Option Care Health during the 4th quarter worth approximately $26,000. Signaturefd LLC increased its position in shares of Option Care Health by 487.9% during the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company's stock worth $28,000 after buying an additional 1,005 shares during the period. Quadrant Capital Group LLC raised its stake in Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock worth $40,000 after buying an additional 1,099 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Option Care Health by 21.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after buying an additional 332 shares during the period. Finally, Johnson Financial Group Inc. acquired a new position in Option Care Health in the fourth quarter valued at $47,000. Institutional investors and hedge funds own 98.05% of the company's stock.

Analyst Upgrades and Downgrades

OPCH has been the subject of several research analyst reports. JMP Securities reissued a "market outperform" rating and issued a $36.00 price objective on shares of Option Care Health in a research report on Wednesday, June 18th. UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. Finally, Barrington Research restated an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Option Care Health has a consensus rating of "Moderate Buy" and a consensus target price of $35.50.

Option Care Health Stock Down 0.7%

Shares of NASDAQ:OPCH traded down $0.21 during trading on Wednesday, reaching $30.64. 880,572 shares of the stock were exchanged, compared to its average volume of 1,858,496. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The stock has a fifty day moving average of $31.93 and a two-hundred day moving average of $31.26. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.54 and a quick ratio of 1.02. The firm has a market cap of $5.02 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 1.87 and a beta of 0.73.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The company's quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. Research analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.